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INTROduCTION Serious adverse effects of long 
acting β‑agonists (LABAs) in patients with asth‑
ma have been suggested by randomized trials 
of salmeterol versus salbutamol by Castle et al.1, 
versus placebo in the SMART study by Nelson 
et al.2, and recently by systematic reviews of sal‑
meterol and formoterol together3 or salmeter‑
ol alone4, both heavily influenced by the study 
of Nelson et al.2 These harmful effects have in‑
cluded severe asthma exacerbations requiring 
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Outcome measures Pre‑specified outcomes in‑
cluded: asthma‑related death; asthma‑related 
non‑fatal intubation and ventilation; asthma‑re‑
lated non‑fatal hospitalization; asthma‑related 
non‑fatal serious adverse events (SAE); death 
from all causes (total death).
The pre‑specified secondary outcomes were: 
total non‑fatal intubation and ventilation; total 
non‑fatal hospitalization; total non‑fatal SAE; 
asthma‑related death or intubation, and total 
death or intubation. We accepted the authors’ or 
manufacturer’s classifications of events as asth‑
ma‑related or non‑asthma‑related.
search strategy (identification of studies) We con‑
ducted searches of MEDLINE, EMBASE, ACPJC, 
and Cochrane (Central) as well as the AstraZene‑
ca web site (http://www.astrazenecaclinicaltrials.
com/article/511012.aspx). The search was updated 
up to April 2008. In addition, we asked the man‑
ufacturer of formoterol (AstraZeneca) to indicate 
all primary studies fulfilling our criteria but not 
previously identified.
Screening of titles/abstract and subsequent‑
ly evaluation of full texts was done by two inde‑
pendent reviewers (Roman Jaeschke and either 
Jan Brożek, Filip Mejza, Parameswaran Nair or 
Wiktoria Leśniak).
data extraction 2 reviewers independently ex‑
tracted data from the articles and single manufac‑
turer documents, reconciling differences by con‑
sensus. In addition to reviewing published data 
we asked corresponding authors and indepen‑
dently the manufacturer to provide information 
regarding the outcomes of inter est and clarifi‑
cation of selected methodo logical details (con‑
cealment of randomization, blinded assessment 
and classification of outcomes, blinding of pa‑
tients and care‑givers, funding source). Final data 
on outcome measures were obtained from pub‑
lished reports, authors, and in each case sought 
from manufacturers. Discrepancies were resolved 
by contacting the study sponsor.
Analysis The data were analyzed using RevMan 
5.0 (Cochrane Review Manager, Cochrane Col‑
laboration, Oxford, UK) using the DerSimonian 
and Laird random effect model.11 Studies with no 
events were excluded in all analyses. In each case 
we analyzed the number of patients with a giv‑
en outcome allowing only one outcome in a given 
category per patient. We decided, a priori, to re‑
strict the formal statistical analyses to variables 
in which 6 or more events occurred. We used 
a random effects model to pool results from dif‑
ferent studies as odds ratio (OR) [95% confidence 
inter val] (OR <1.0 favors formoterol).
Heterogeneity was explored with the use 
of methods included in RevMan (I2 and χ2) as 
well as by performing univariate and multivari‑
able meta ‑regressions to investigate the following 
a priori hypotheses of factors potentially influ‑
encing effect size: dose of ICS used in the control 
hospitalization, life threatening exacerbations re‑
quiring intubations, and asthma‑related death.5 
The above reports, however, included data from 
clinical settings in which inhaled steroids were 
not required in all patients. These patients were 
thus not treated according to current asthma 
management guidelines which have consistent‑
ly recommended that LABAs should only be 
used in combination with inhaled corticoster‑
oids (ICS).6,7 We have recently published a sys‑
tematic review and meta‑analysis looking specifi‑
cally at the impact of LABAs (formoterol and sal‑
meterol) on these most serious outcomes in pop‑
ulation of patients with mandatory ICS use.8 Our 
results suggested that in such patients LABAs 
did not increase the risk of asthma‑related hos‑
pitalizations and asthma related serious adverse 
events. Asthma‑related deaths and intubations 
were too infrequent to establish LABA’s relative 
effect on these outcomes.
In this paper we present data regarding for‑
moterol use alone; data concerning salmeterol 
were recently published by Bateman et al.9 Some 
of the results of this study have been previously 
reported in an abstract.10
PATIENTs ANd mEThOds The details of meth‑
ods were reported in the main manuscript.8 Key 
points are presented below.
Eligibility criteria All included studies had 
the following characteristics: treatment alloca‑
tion by randomization; para llel control groups 
(cross‑over studies excluded) with at least 12 
weeks of treatment; blinding of patients and 
care‑givers; acceptable follow‑up of patients 
receiving study medication (outcome data for 
the full duration of planned treatment missing 
for <20% of patients taking formoterol in trials <3 
month long, <30% for over 3 months to less than 
1 year long, <40% for one year or longer). Eligible 
studies involved patients with asthma (excluding 
children younger than 12 years); all patients had 
to be receiving at least some ICS.
Intervention group Formoterol used regularly 
twice a day in addition to ICS. Formoterol and 
ICS could be delivered through single or through 
separate devices and patients could be receiving 
ICS as part of study medication or as non‑study 
treatment required by the study protocol.
Control group Eligibility required that all pa‑
tients in the control group used ICS, either as 
a part of study protocol (study medication) or as 
a required background therapy. The dose of ICS 
need not have been the same in inter vention and 
control groups. We excluded studies in which con‑
trol patients received regular LABA or regular 
short acting β‑agonist. We also excluded studies 
in which the control group, in addition to ICS, re‑
ceived another asthma study medication (leukot‑
riene receptor antagonist, theophylline).
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received more ICS than patients in the formoterol 
group; the difference between the groups is thus 
potentially related to both use of formoterol and 
to different ICS doses. In TAbLE 4 we present the re‑
sults of meta‑analysis including all 16 studies.
Considering all 16 studies, there were 2 asth‑
ma‑related deaths (both in formoterol groups, 
in two separate studies) and no asthma‑related 
non‑fatal intubations. One of the deaths occurred 
in a 35 year old female after an 8 day hospital‑
ization for a severe asthma attack leading to in‑
tubation, ventilation, and nosocomial pneumo‑
nia with septic shock. The second death occurred 
in a 65 year old male who developed dyspnea 
and chest pain and died on admission to hospi‑
tal despite attempts at cardio‑pulmonary resus‑
citation. There were 8 additional deaths included 
in the “total mortality” category: 5 in the formot‑
erol‑ICS group: 2 categorized as suicide, 1 as pul‑
monary embolism, 1 as due to malignant meta‑
static disease and 1 as sudden death. 3 deaths 
in the ICS group were categorized as due to myo‑
cardial infarction, hypertrophic cardiomyopathy, 
and due to unknown cause respectively. The OR 
for total mortality was 1.22 (95% CI 0.38–3.90) 
based on those 7 deaths in formoterol groups and 
3 deaths in control groups; with one additional 
non‑fatal intubation in each treatment category 
the OR for total mortality or intubation was 1.16 
(95% CI 0.38–3.57). There were too few events 
to analyze the relative incidence of most serious 
asthma‑related events‑deaths and intubations 
(2 deaths, both in formoterol groups, and zero 
asthma‑related intubations). The differences be‑
tween groups in other outcomes included less 
asthma related hospitalizations (OR 0.59, 95% CI 
0.37–0.93) and less asthma‑related serious ad‑
verse events (heavily influenced by hospitaliza‑
tions, OR 0.58, 95% CI 0.37–0.91; there were only 
5 SAEs which were not hospitalizations) (TAbLE 4, 
FIGuRE). The trend towards reduction in the inci‑
dence of those outcomes was statistically signif‑
icant in the subgroup of studies using the same 
dose of ICS in all patients (TAbLE 2, FIGuRE).
Exploration of heterogeneity There was no evi‑
dence against the homo geneity or consistency 
of treatment effects among studies for all out‑
comes usingα = 0.10 level of significance.
Examination of the a priori hypotheses to ex‑
plore or explain the residual heterogeneity (sim‑
ilarity of ICS dose in the formoterol and control 
group, daily dose of formoterol, and the mode 
of drug delivery investigated, each for several 
outcomes) revealed no statistically significant 
impact in all cases.
The results remained unchanged (no change 
in statistical significance and no important 
change in OR estimate) when we included 
3 studies in which formoterol was administered 
to all or some patients only once daily (2003 
Buhl, 2006 Rabe, 2006 Kuna). Combining fa‑
tal and non‑fatal asthma related events (add‑
ing deaths to non‑fatal hospitalizations and 
group (similar dose of ICS to formoterol group or 
increased dose); daily dose of formoterol (9 mi‑
crograms per day vs. more); and use of ICS as part 
of study medications in single device with formot‑
erol, in separate study devices, or as a non‑study 
background medication. These analyses were per‑
formed using STATA (version 10.1). In the uni‑
variate and multivariable analysis, the criterion 
for statistical significance for each of the above 
analyses, performed using a t‑test, was set a pri‑
ori atα = 0.10.
For the estimation of number of patient‑years 
on formoterol treatment we assumed that pa‑
tients who did not complete the total duration 
of follow up for a given study received medication 
assigned by randomization for 50% of the study 
duration (i.e. for 12 weeks in 24‑week studies).
REsuLTs Our analysis included 16 studies iden‑
tified in course of the process described previous‑
ly.8 These publications are listed in Appendix A, 
the details about included studies are provided 
in Appendix C of the previous publication.8 All 
these studies used concealed randomization pro‑
cedures, and in all cases assignment of ‘asthma‑re‑
lated’ to an event was done without knowledge 
of treatment used. All were sponsored by Astra‑
Zeneca. Two studies using formoterol fumarate 
(Foradil) were sponsored by Novartis or its prede‑
cessor (Ciba‑Geigy).12,13 As we have not obtained 
complete data, those studies are not included 
in the analyses. However, the authors of prima‑
ry reports of those studies, while reviewing safe‑
ty, did not indicate either death or intubation as 
events in the study. Three additional studies ful‑
filled all inclusion criteria except that formot‑
erol was administered to at least some patients 
only once daily (2003 Buhl, 2006 Rabe, 2006 
Kuna; included in TAbLE 1 and APPENdIx, but not 
considered in primary analysis). We have exam‑
ined the impact of those 3 studies on the results 
using sensitivity analysis (including or exclud‑
ing them in different combinations) and found 
no significant effect.
Among included studies 10 used similar doses 
of ICS in both groups, and six used higher dose 
of ICS in the control group than in those taking 
formoterol. For one study we excluded children 
below 12 years of age (stratified at randomiza‑
tion, study label ‘2005 O’Byrne’). Together this 
group of 16 studies included 10,638 participants 
(5,996 taking formoterol) and provided approx‑
imately 4,200 patient‑years observation in for‑
moterol groups.
In TAbLE 1 we present the number of events 
in different outcome categories identified in all 
16 studies included in the analysis (and in 3 stud‑
ies not included). In TAbLE 2 we present the re‑
sults of meta‑analysis of the same events in ten 
studies in which all patients were on similar dose 
of ICS, in those studies the difference between 
the groups are likely related to use of formoterol 
only. In TAbLE 3 we show results of combined anal‑
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We favor thus the remaining hypothesis ex‑
plaining the differences in results – that the prog‑
nosis of asthma and the potential effects of LABA 
in general and formoterol in this case taken reg‑
ularly are different among patients taking and 
not taking concomitant inhaled corticosteroid. 
This hypothesis suggests that ICS provides both 
protection against severe asthma deterioration 
and protection against the potential harmful ac‑
tions of LABA by controlling components of air‑
way inflammation, notably by decreasing air‑
way eosinophil, lymphocyte and mast cell num‑
bers. When LABA is used without concomitant 
ICS, this inflammatory response may not be ad‑
equately controlled, potentially leading to asth‑
ma worsening.14
The main limitations of this study are exclu‑
sion of children less than 12 years of age and in‑
ability to obtain full data from non AstraZeneca 
sponsored studies.
In summary, our systematic review evaluated 
the safety of adding formoterol to ICS and did not 
reveal convincing evidence of harm. We have ex‑
tended previous reports that addition of LABA 
has no detrimental effect on the number of asth‑
ma‑related hospitalizations and SAEs in patients 
receiving ICS.9,15 Due to the very low frequen‑
cy of most serious events we have not exclud‑
ed the possibility of a relative increase in deaths 
in patients receiving formoterol who are also us‑
ing ICS. We have demonstrated that, in popula‑
tions similar to those included in the eligible trials, 
any deleterious effect of formoterol on death or 
intubations in patients receiving ICS is – if it ex‑
ists – small in absolute terms. The extent to which 
our results, taken together with evidence of symp‑
tomatic benefits of LABA16,17 are reassuring re‑
garding the use of formoterol in patients receiv‑
ing ICS may differ among physicians, patients, 
and policy‑makers.
External funding This study was done without 
any external funding.
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non‑fatal SAE) also had no important effect 
on the results.
dIsCussION This systematic review and meta‑
‑analysis of the effect of formoterol in combina‑
tion with ICS on serious harmful effects in clin‑
ical trials of asthma did not show an increased 
risk for hospitalizations or serious adverse events; 
in fact the direction of effect appears beneficial. 
The relative effect on asthma related mortali‑
ty and asthma related intubation and ventila‑
tion could not be assessed because of the very 
low number of those events. This contrasts with 
the report of Nelson et al. related to salmeterol 
(SMART study)2 and the subsequent systemat‑
ic review and the meta‑analysis by Salpeter et al. 
which included both formoterol and salmeterol 
studies3 – those authors reported increased risk 
of deaths and life threatening asthma experi‑
ences as well as an increase in the risk of asthma‑
‑related hospitalization (OR for hospitalizations 
in all studies combined 2.6, 95% CI 1.6–4.3, for 
salmeterol studies OR 1.7, 95% CI 1.1–2.7 and 
for formoterol studies OR 3.2, 95% CI 1.7–6.0),3 
all in settings in which ICS use was not required 
in all patients. Similarly, a recent Cochrane review 
of 62,630 patients in trials comparing salmeter‑
ol with placebo or salbutamol in which ICS use 
was again not mandated in all patients also found 
an increase in non‑fatal serious adverse events re‑
lated to use of salmeterol against placebo (among 
over 31,000 adults: OR 1.14, 95% CI 1.01–1.28).4 
Our own analyses, both when looking at com‑
bined LABA data8 and formoterol alone (this pa‑
per) did not confirm those findings in a setting 
mandating use of ICS.
We have discussed potential reasons for this 
difference in our previous paper.8 Our conclu‑
sions were that the differences were unlikely 
due to underlying asthma severity, shorter ex‑
posure to long acting β‑agonist or differences be‑
tween the randomized trials we examined (phase 
3 studies) and the studies suggesting an increased 
mortality with LABA (post‑marketing or phase 
4 studies). The possibility that a lack of statisti‑
cal power to detect a real difference was playing 
a role – after all both asthma related deaths and 
majority of all deaths occurred among patients 
on formoterol – can not be excluded. Our results 
do not exclude thus a relative increase in asthma 
related deaths, but show that the absolute in‑
crease in formoterol associated deaths or intuba‑
tions from asthma in populations such as those 
participating in these trials, if it exists, is small 
(2 deaths and 0 non‑fatal intubations in almost 
6,000 patients receiving formoterol during more 
than 4,000 patient ‑year observations). Further‑
more, in contrast to the Salpeter et al.3 and Co‑
chrane4 meta‑analyses our results exclude an im‑
portant increase in asthma‑related hospitaliza‑
tions or serious adverse events, and strongly sug‑
gest the possibility of benefit of formoterol used 









Asthma‑related mortality 1 1/0 –
Asthma‑related non‑fatal intubation 0 0/0 –
Asthma‑related non‑fatal intubation or death 1 1/0 –
Asthma‑related non‑fatal hospitalization 6 10/24 0.46 (0.23 –0.93)
Asthma‑related non‑fatal SAE 6 11/25 0.45 (0.23–0.90)
Total mortality 4 4/0 –
Total non‑fatal intubation and ventilation 1 0/1 –
Total non‑fatal intubation or death 4 4/1 –
Total non‑fatal hospitalization 9 69/72 0.87 (0.61–1.22) 









Asthma‑related mortality 1 1/0 –
Asthma‑related non‑fatal intubation 0 0/0 –
Asthma‑related non‑fatal intubation or death 1 1/0 –
Asthma‑related non‑fatal hospitalization 5 22/22 0.70 (0.38–1.29)
Asthma‑related non‑fatal SAE 5 23/24 0.69 (0.38–1.26)
Total mortality 2 3/3 0.71 (0.13–3.91)
Total non‑fatal intubation and ventilation 1 1/0 –
Total non‑fatal intubation or death 2 4/3 0.91 (0.17–4.70)
Total non‑fatal hospitalization 6 130/87 1.07 (0.81–1.42)









Asthma‑related mortality 2 2/0 –
Asthma‑related non‑fatal intubation 0 0/0 –
Asthma‑related non‑fatal intubation or death 2 2/0 –
Asthma‑related non‑fatal hospitalization 11 32/46 0.59 (0.37–0.93)
Asthma‑related non‑fatal SAE 11 34/49 0.58 (0.37–0.91)
Total mortality 6 7/3 1.22 (0.38–3.90)
Total non‑fatal intubation and ventilation 2 1/1 –
Total non‑fatal intubation or death 6 8/4 1.16 (0.38–3.57)
Total non‑fatal hospitalization 15 199/159 0.98 (0.79–1.23)
Total non‑fatal serious adverse event 15 228/177 1.00 (0.81–1.23)
Abbreviations: see TAbLE 1
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2006 Pohl (bA‑039‑0001)  Pohl WR, Vetter N, Zwick H, Hrubos W. Ad‑
justable maintenance dosing with budesonide/formoterol or budesonide: 
Double‑blind study. Respir Med. 2006: 100: 551‑560.
studies with once daily dose of formoterol in some 
patients
2003 buhl (sd‑039‑0666) (ICs dose the same in control group)  Buhl 
R,  Creemers  JPHM,  Vondra  V,  et  al.  Once‑daily  budesonide/formoterol 
in a single inhaler in adults with moderate persistent asthma. Respir Med. 
2003; 97: 323‑930.
2006 Rabe (sd‑039‑0667) (ICs dose higher in control group)  Rabe 
KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhal‑
er for maintenance and relief in mild‑to‑moderate asthma – A randomized, 
double‑blind trial. Chest. 2006; 129: 246‑256.
